Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line WT1-targeted dendritic cell vaccination for malignant pleural mesothelioma
2014-001099-75Phase 2Active
- Sponsor
- Antwerp University Hospital
- Start
- Jul 2015
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in pleural mesothelioma, sponsored by Antwerp University Hospital. Primary endpoint: Feasibility and safety. Started Jul 2015; status: active.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2014-001099-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001099-75.